3 completed, 3 unknown, 1 no longer available, 1 recruiting. 3 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Completed 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow Penicillamine: new trials by email Literature Review of Penicillamine trials Research Report on Penicillamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. TETA 4HCl formulation, D-Penicillamine - Wilson's Disease | Phase 3 | Recruiting | Orphalan | 38 | 2026-09-03 | 2026-10-15 |
| Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer Penicillamine - Head and Neck Cancer, Recurrent Cancer | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 10 | 2023-11-15 | 2023-11-18 |
| The Individual Therapy for Patients With Wilson's Disease DMPS, Penicillamine, DMSA - Wilson's Disease | Early Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 400 | 2019-03-15 | 2019-05-21 |
| Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease Penicillamine (D1-W12), TETA 4HCL (W12-60), Penicillamine (W12-W60) - Wilson Disease | Phase 3 | Completed | Orphalan | 77 | 2018-09-03 | 2025-07-02 |
| Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis Placebo, Ascorbic Acid, Cuprimine Oral Product - Arteriovenous Fistula Occlusion | Phase 2 | Unknown | Southeast Renal Research Institute | 30 | 2017-02-01 | 2017-09-11 |
| Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria Tiopronin 1g per day, Tiopronin 2g per day, Tiopronin 3g per day - Cystinuria | Phase 4 | Completed | NYU Langone Health | 10 | 2012-06-01 | 2021-08-23 |
| Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma penicillamine, radiation therapy - Brain and Central Nervous System Tumors | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 40 | 1999-03-01 | 2012-05-03 |
| Post Marketing Surveillance Study of Cuprimine Cuprimine (penicillamine) - Scleroderma | No longer available | Merck Sharp & Dohme LLC | 2015-10-22 |
Hepatolenticular Degeneration (3) · Central Nervous System Neoplasms (1) · Cystinuria (1) · Glioblastoma (1) · Gliosarcoma (1) · Head and Neck Neoplasms (1) · Recurrence (1) · Scleroderma, Diffuse (1)
Orphalan (2) · Merck Sharp & Dohme LLC (1) · NYU Langone Health (1) · Nanfang Hospital, Southern Medical University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Southeast Renal Research Institute (1)
United States (5) · China (3) · Belgium (1) · Brazil (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Pakistan (1) · Poland (1) · Saudi Arabia (1) · United Kingdom (1)
David S Goldfarb, MD (1) · James A Tumlin, MD (1) · Jian Guan, M.D (1) · Steven Brem, MD (1) · Zhi-Ying Wu, MD&PhD (1)
PMID 16053699, PMID 36183738, PMID 39139457, PMID 41831608
U01CA062475 (1), U54DK083908 (1)